Menu
close
Menu
close
Menu
close
Menu
close
Menu
close
Menu
close

Meet our Leadership Team

Our executive team, board, and scientific personnel are a diverse mix of ages, genders, backgrounds, and ethnicities, with more than 80% holding PhDs with specialties from cell biology to computer science.

Decades of experience, dozens of perspectives

We value diversity of background and mindset just as highly as experience and technical knowledge.
Our executive team, board, and scientific personnel are a diverse mix of ages, genders, backgrounds, and ethnicities, with more than 80% holding PhDs with specialties from cell biology to computer science.
It’s this diversity and originality, powered by a shared passion for delivering innovative healthcare solutions for all, that truly makes the SOPHiA GENETICS team unique.

Our Executive Team

Jurgi Camblong
Founder and CEO
Ross Muken
President
George Cardoza
EVP – Chief Financial Officer
Philippe Menu
EVP – Chief Medical Officer & Chief Product Officer
Manuela Valente
EVP – Chief People Officer
Daan Van Well
EVP – Chief Legal and Regulatory Officer
Zhenyu Xu
EVP – Chief Scientific Officer
Abhimanyu (Abhi) 
Verma
SVP – Chief Technology Officer
Kevin Puylaert
VP – Managing Director, EMEA

Board of Directors

Jurgi Camblong
Founder and CEO
Troy Cox
Chairman of the Board
Kathy Hibbs
Board Member
Didier Hirsch
Board Member
Vincent Ossipow
Board Member
Tomer Berkovitz
Board Member
Jean-Michel Cosséry
Board Member

Philippe Menu

EVP – Chief Medical Officer & Chief Product Officer

LinkedIn
Philippe Menu, M.D., Ph.D., M.B.A., brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology, and business management consulting. He joined SOPHiA GENETICS in February 2020 as Chief Medical Officer, and in March 2023 was appointed Chief Product Officer and Chief Medical Officer.
Prior to joining SOPHiA GENETICS, Philippe spent 8 years at McKinsey & Company serving dozens of clients in the BioPharma sector. He advised global pharmaceutical companies, mid-size players, and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases.
Prior to that, Philippe was a post-doctoral fellow at the University of Lausanne.

Philippe holds an M.D. and a Ph.D. from the University of Lausanne, and an M.B.A. in life sciences from the Open University Business School.

Manuela Valente

EVP – Chief People Officer

LinkedIn
Manuela Da Silva Valente, B.A., is a seasoned human resources executive with more than 20 years of experience working in international companies. Manuela joined SOPHiA GENETICS in January 2019 as our Chief People Officer from IQVIA (formerly Quintiles and IMS Health, Inc.), a human data science company, where she had a number of senior human resources roles, including from 2016 to 2018 the position of Global Senior Director of Human Resources.
Prior to this, she worked for several years at Outcome Sciences, where she successfully established European operations and led the organization through an acquisition by Quintiles.
Manuela obtained a Bachelor’s degree in business administration from the Business Management School of Zurich and a management & human resources diploma from CEFCO Lausanne.
Used to working in fast-pacing companies, Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes by focusing on talent development and employee engagement.

Abhimanyu (Abhi) Verma

SVP – Chief Technology Officer

LinkedIn
Abhimanyu (Abhi) Verma, M.Sc., M.B.A., is a healthcare technology leader experienced in developing capabilities and leading multifunctional organizations to create and accelerate solutions that impact patients and joined SOPHiA GENETICS in February 2022. He has more than 17 years of life sciences industry experience centered on harnessing the intersection of people, science, technology, data & AI serving multiple therapeutic areas and functions across the pharma value chain.
His leadership experience spans creating technology & information strategies; operating models; building teams and products; running operational platforms; and driving organizational and cultural transformation, with a relentless focus on outcomes and execution. Previously at Novartis, Abhi has proven to be a thought leader and execution champion at innovating and scaling data science and technology products, methodologies and approaches.
Passionate about cycling, comics, science fiction, and history, Abhi holds an M.B.A. from the Indian School of Business, a Master of Science in pharmaceutical medicine and is an engineer. He is also co-founder of the nonprofit Health Hacking Lab.

Zhenyu Xu

EVP – Chief Scientific Officer

LinkedIn
Zhenyu Xu, Ph. D., is a genome scientist with a background in molecular and computational biology. Zhenyu is among the most experienced bioinformaticians in clinical NGS data analysis worldwide. He joined SOPHiA GENETICS in January 2012 and is the leader of the technology team that developed the SOPHiA DDM™ platform – the universal technology for data-driven medicine.
Zhenyu has served as our Chief Scientific Officer since January 2021 and was previously our Chief Technology Officer since May 2014. Prior to that, Zhenyu was a post-doctoral fellow at the European Molecular Biology Laboratory.
Zhenyu holds an M.Sc. in molecular and computational biology from Cambridge University and obtained his Ph.D. at the European Molecular Biology Laboratory, where he focused on the transcriptome landscape of yeast. His Ph.D. work systematically characterized the non-coding transcripts in yeast that lead to the unveiling that, in a majority of cases, transcriptions are bidirectional.

Ross Muken

President

LinkedIn
Ross Muken, B.Sc., is a seasoned executive with more than 20 years of experience across life sciences, health technology, medical devices, and pharma services. Ross joined SOPHiA GENETICS in February 2021 as Chief Financial Officer, and in March 2023 was appointed, Chief Financial Officer & Chief Operating Officer.  In November 2024, Ross was appointed President.
Before joining SOPHiA GENETICS, he was CFO & COO of Click Therapeutics.
Prior to that, he was partner, Senior Managing Director and head of the healthcare services & technology equity research team at Evercore/ISI Group, where he covered more than 50 companies across the healthcare technology & distribution, life science tools & diagnostics, managed care & facilities and medical supplies & devices subsectors.

Earlier in his career, Ross served as Senior Managing  Director at Deutsche Bank Securities and was part of the equity research division at Thomas Weisel Partners. His professional journey began as an M&A investment banker at Bank of America Securities after graduating from Boston University magna cum laude with a B.Sc. in business administration.

Daan Van Well, 
LL.M., M.B.A.

EVP, Chief Legal & Regulatory Officer

LinkedIn
As Executive Vice President, Chief Legal & Regulatory Officer, Daan leads Legal Affairs, Regulatory Affairs, Quality Assurance, Risk & Compliance, and Information Security at SOPHiA GENETICS. With over 25 years of experience in top-tier private practice, in-house, and consulting roles, Daan brings extensive expertise in legal, governance, and compliance.
Daan joined SOPHiA GENETICS in June 2019 as General Counsel. Before this role, he served as Head of Legal Services at PwC in Geneva, where he advised on business process optimization, commercial transactions, mergers and acquisitions, business development, governance, and compliance. Prior to PwC, Daan was Group Corporate Secretary at international food retailer Ahold (now Ahold Delhaize), where he oversaw corporate finance, governance, and investor relations for the New York Stock Exchange- and AEX Euronext Amsterdam-listed company.
He began his career at the top-tier international law firm Loyens & Loeff in Rotterdam, The Netherlands, where he gained a strong foundation in corporate law and regulatory matters.
Daan holds an LL.M. in Civil Law from Utrecht University and an Executive M.B.A. in Management and Corporate Finance from HEC Lausanne.

Kevin Puylaert

VP – Managing Director, EMEA

LinkedIn
Kevin Puylaert is the Managing Director of EMEA at SOPHiA GENETICS. He joined the company in March 2016. With a passion for innovation and a drive to bring solutions to healthcare professionals around the world, Kevin leads the company’s efforts to accelerate the adoption of the SOPHiA DDM™ Platform in Europe, the Middle East and Africa.
With his industry expertise and entrepreneurial spirit, Kevin has been instrumental in the growth of SOPHiA GENETICS, driving the company’s global expansion through his expertise in developing and executing successful business strategies. Under his leadership, Kevin spearheaded the company’s expansion outside of Europe for the first time, successfully introducing SOPHiA GENETICS to APAC, LATAM and the US, and launched the company’s Boston office, serving as General Manager for several years before returning to Europe to lead Business Development.
With a background in science and business, Kevin holds a Master’s degree in science from the Louvain School of Management, Belgium, and a Bachelor’s degree in business engineering from the University of Leuven, Belgium.

George Cardoza

EVP – Chief Financial Officer

LinkedIn
George Cardoza, M.B.A.  joined the SOPHiA GENETICS leadership team as Chief Financial Officer in November 2024. Prior to joining SOPHiA GENETICS, he was the Chief Financial Officer and Head of Service Delivery for Biocartis. He joined Biocartis from Accuragen, where he was the Chief Executive Officer.
Before leading Accuragen, George spent over twelve years with NeoGenomics in various leadership roles including Chief Financial Officer, President of Pharma Services and Chief Operating Officer. He also spent more than fourteen years with Quest Diagnostics in various roles including the Controller of the Central Region.
George holds a Bachelor of Science degree from Syracuse University with a dual major in Finance and Accounting, and a Masters in Business Administration from Michigan State University.

Jurgi Camblong

Co-Founder and CEO

LinkedIn
Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.
He is a molecular biologist (published in Cell, Science and Nature), has a PhD in life sciences from the University of Geneva and an EMBA in management of technology from EPFL/HEC Lausanne.
In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Jurgi has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.

Troy Cox

Chairman of the Board

LinkedIn
Troy Cox, M.B.A, is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (acquired by Roche in 2018), Troy is making a difference in patient’s lives by serving on corporate boards of innovative companies in the BioPharma, diagnostics and tech industries.
He is also committing his support to patient-focused non-profit organizations. In June 2019, Troy joined SOPHiA GENETICS as the chairman of the board of directors to help the organization further advance data-driven medicine. From 2017 to 2019, Troy served as the Chief Executive Officer of Foundation Medicine, Inc.
Prior to Foundation Medicine, Troy served as the Senior Vice President of U.S. Commercial of Genentech, Inc. where he led US bio-oncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Prior to that, Troy held various executive and senior positions at UCB S.A., Sanofi-Aventis U.S. LLC and Schering-Plough Corporation. In addition to our board of directors, Troy serves on the board of directors of Zymeworks, Inc., LetsGetChecked, Somalogic, Inc., BioSplice Therapeutics, Inc. and previously served on the board of directors of Foundation Medicine, Inc.
Troy’s expertise spans across strategy, general management, commercial and R&D. His pharmaceutical career began as a sales representative after earning his MBA at the University of Missouri. He has also received a B.B.A. in finance from the University of Kentucky.

Kathy Hibbs

Board Member

LinkedIn
Kathy Hibbs, J.D., is an accomplished healthcare technology executive and active board member with more than two decades of expertise in healthcare and genomics. Since 2022, she has served as the Chief Administrative Officer of 23andMe and prior to that role as the Chief Legal and Regulatory Officer of 23andMe from 2014 to 2022, where she leads its complex legal operations and regulatory affairs. She is globally recognized for her effectiveness, having successfully pioneered the first FDA clearance for over-the-counter genetic testing.
Regularly recognized as one of the Bay Area’s most influential women by both the San Francisco Business Times and Silicon Valley Business Journal, Kathy is ranked by Chambers as among the most influential general counsel in the US. She sits on the board of Cadex Genomics, Inc. and previously served on the board of directors of Decipher Biosciences, Inc. During her 15 years as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX), Monogram Biosciences, Inc. (NASDAQ: MGRM) and in the leadership team of Varian Medical Systems, Inc. (NASDAQ: VAR) involved in legal, business development and compliance matters, Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients. Kathy graduated summa cum laude from the University of California, Riverside, where she received her J.D. from Hastings College of Law.

Didier Hirsch

Board Member

LinkedIn
Didier Hirsch, M.Sc., M.S., has served as a member of our board of directors since June 2020. Didier Hirsch was Senior Vice President and Chief Financial Officer of Agilent Technologies, Inc., a global leader in life sciences, diagnostics and applied chemical markets, from 2010 to 2018. He joined Agilent in 1999 at its inception, holding multiple leadership roles in finance.
Prior to joining Agilent Technologies, Inc., Didier was with Hewlett-Packard Company, serving in leadership roles in finance and administration in EMEA and Asia Pacific beginning in 1989. Previously, he held finance positions at Valeo Inc., Gemplus S.C.A., SGS-Thomson Microelectronics, I.B.H. Holding S.A., Bendix Corporation and Ford Motor Company.
Didier serves on the board of directors of Knowles Corporation and previously served on the board of directors of Logitech International S.A. and International Rectifier Corporation. He is the chair of the audit committee and a member of its nominating committee.
Didier holds an M.S. in computer science from Toulouse University in France and an M.Sc. in industrial administration from Purdue University in the US.

Vincent Ossipow

Board Member

LinkedIn
Vincent Ossipow, Ph.D., CFA has served as a member of our board of directors since June 2014. He has been a partner at Omega Funds, where he served as Chief Scientific Officer of Omega Alpha SPAC, and brings 22 years of healthcare investment experience in public and private companies.
Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a partner for private equity. Prior to that, he was with Pictet Bank where he co-managed the Pictet Biotech Fund.
Vincent has extensive board member experience. In addition to our board of directors, Vincent serves on the board of directors of Immunic, Inc. (NASDAQ: IMUX), BioInvent International AB (STO: BINV), FoRx SA, SwissThera SA, and eTheRNA immunotherapies NV, and previously served on the board of directors of Andrew Alliance S.A., Lifespan, Inc., Raindance Technologies, CNx SA and Kuros Biosciences AG. He served on the board of directors of a dozen public and private companies over the past decade.
As a research fellow at the University of Geneva from 2000 to 2006, where he obtained a Ph.D. in molecular biology, he worked on the molecular basis of brain function.
Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute in Bethesda, Maryland. He completed a certificate in international finance and global markets at the Georgetown University School of Business in Washington, D.C.

Tomer Berkovitz

Board Member

LinkedIn
Tomer Berkovitz, Ph.D., has served as a member of our board of directors since March 2021. Since 2018 he has served as a General Partner at aMoon, where he co-leads aMoon’s Growth Fund. As a former investment banker and senior executive in public companies, Tomer witnessed how the sectors of healthcare and technology were converging into a new industry that had the potential to make a global impact.
Tomer places his relationship with our portfolio companies’ CEOs and founders as his top priority, partnering with entrepreneurs to enhance the value and growth of their company. Since joining aMoon in early 2018, Tomer has led the $55M Series D round of Seer (NASDAQ: SEER) and supported the company through additional private financing, spin-off and successful IPO. Tomer also led the $55M Series B of PrognomIQ and the $30M Series C round of Zebra Medical Vision, serving as a board member in both companies. Tomer also led SOPHiA GENETICS’ $110M Series F round and serves as the Chairman of its Strategy Committee.
Tomer started his Wall Street career as an investment banker at J.P. Morgan in New York, where he was promoted to a position as executive director in record time. In this role, he led numerous capital market and mergers and acquisitions transactions. After J.P. Morgan, Tomer was appointed CFO & COO of Alcobra Ltd., a NASDAQ–listed biopharmaceutical company, where he served as Chief Operating Officer and Chief Financial Officer and led public equity offerings and its merger with Arcturus Therapeutics. Tomer earned his Ph.D. in finance (with distinction) from Columbia Business School.

Jean-Michel Cosséry

Board Member

LinkedIn
Jean-Michel Cosséry, Ph.D., Pharm.D., M.B.A is a senior healthcare executive with global leadership experience in research, marketing, and commercial roles in med-tech and pharmaceuticals and has served as a member of our board of directors since June 2022 From 2012 to 2018, Jean-Michel served in various senior leadership positions at Eli Lilly and Company, including as Vice President, North America Oncology, as well as Vice President and Managing Director of Lilly UK and Northern Europe. Prior to that, he served as Vice President and Chief Marketing Officer of GE Healthcare as well as in senior positions at Novartis International AG and Serono (now Merck (Schweiz) AG). Jean-Michel serves on the board of directors of Malin Corporation plc, Exact Therapeutics AS, and Eracal Therapeutics Ltd., and serves as the non-executive chairman of Scancell Holdings PLC. Previously, he served on the board of directors of ABPI (UK) LIMITED, Immunocore Holdings Limited, until its IPO, Kymab Ltd, until its sale to Sanofi, and Diurnal PLC, and as chairman of the board of directors of the American Pharmaceutical Group in the UK.
Jean-Michel holds an M.B.A. from the Rotterdam School of Management and a Ph.D. with honors in nuclear chemistry and neurobiology from Paris Sud University. Additionally, he holds a Pharm.D. with honors in pharmacology from Paris.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview
SOPHiA DDM™ for Genomics
SOPHiA DDM™ for Radiomics
SOPHiA DDM™ for Multimodal
Professional Services
SOPHiA DDM™ Overview
Unlocking Insights, Transforming Healthcare
Learn About SOPHiA DDM™ 
SOPHiA DDM™ for Genomics

Oncology 

Rare and Inherited Disorders

Add-On Modules

SOPHiA DDM™ for Radiomics
Unlock entirely novel insights from your radiology images
Learn About SOPHiA DDM™ for Radiomics 
SOPHiA DDM™ for Multimodal
Explore new frontiers in biology and disease through novel insights
Learn About SOPHiA DDM™ for Multimodal
Professional Services
Accelerate breakthroughs with our tailored enablement services
Learn About our Professional Services
magnifiercross